# Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)

> **NCT06393504** · — · ACTIVE_NOT_RECRUITING · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 2095 (estimated)

## Conditions studied

- Insomnia Disorder

## Interventions

- **DRUG:** Daridorexant
- **DRUG:** Non-orexin receptor antagonist insomnia medication
- **OTHER:** No insomnia medication

## Key facts

- **NCT ID:** NCT06393504
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 2095 (ESTIMATED)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393504, "Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06393504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*